



General Assembly

**Amendment**

January Session, 2023

LCO No. 7894



Offered by:

SEN. LOONEY, 11<sup>th</sup> Dist.

SEN. CABRERA, 17<sup>th</sup> Dist.

To: Senate Bill No. 6

File No. 337

Cal. No. 197

**"AN ACT CONCERNING UTILIZATION REVIEW AND HEALTH CARE CONTRACTS, HEALTH INSURANCE COVERAGE FOR NEWBORNS AND STEP THERAPY."**

1 Strike everything after the enacting clause and substitute the  
2 following in lieu thereof:

3 "Section 1. Section 38a-591a of the general statutes is repealed and the  
4 following is substituted in lieu thereof (*Effective October 1, 2023*):

5 As used in this section, [and] sections 38a-591b to 38a-591n, inclusive,  
6 and sections 2 and 3 of this act:

7 (1) "Adverse determination" means:

8 (A) The denial, reduction, termination or failure to provide or make  
9 payment, in whole or in part, for a benefit under the health carrier's  
10 health benefit plan requested by a covered person or a covered person's  
11 treating health care professional, based on a determination by a health  
12 carrier or its designee utilization review company:

13 (i) That, based upon the information provided, (I) upon application  
14 of any utilization review technique, such benefit does not meet the  
15 health carrier's requirements for medical necessity, appropriateness,  
16 health care setting, level of care or effectiveness, or (II) is determined to  
17 be experimental or investigational;

18 (ii) Of a covered person's eligibility to participate in the health  
19 carrier's health benefit plan; or

20 (B) Any prospective review, concurrent review or retrospective  
21 review determination that denies, reduces or terminates or fails to  
22 provide or make payment, in whole or in part, for a benefit under the  
23 health carrier's health benefit plan requested by a covered person or a  
24 covered person's treating health care professional.

25 "Adverse determination" includes a rescission of coverage  
26 determination for grievance purposes.

27 (2) "Authorized representative" means:

28 (A) A person to whom a covered person has given express written  
29 consent to represent the covered person for the purposes of this section  
30 and sections 38a-591b to 38a-591n, inclusive;

31 (B) A person authorized by law to provide substituted consent for a  
32 covered person;

33 (C) A family member of the covered person or the covered person's  
34 treating health care professional when the covered person is unable to  
35 provide consent;

36 (D) A health care professional when the covered person's health  
37 benefit plan requires that a request for a benefit under the plan be  
38 initiated by the health care professional; or

39 (E) In the case of an urgent care request, a health care professional  
40 with knowledge of the covered person's medical condition.

41 (3) "Best evidence" means evidence based on (A) randomized clinical  
42 trials, (B) if randomized clinical trials are not available, cohort studies or  
43 case-control studies, (C) if such trials and studies are not available, case-  
44 series, or (D) if such trials, studies and case-series are not available,  
45 expert opinion.

46 (4) "Case-control study" means a retrospective evaluation of two  
47 groups of patients with different outcomes to determine which specific  
48 interventions the patients received.

49 (5) "Case-series" means an evaluation of a series of patients with a  
50 particular outcome, without the use of a control group.

51 (6) "Certification" means a determination by a health carrier or its  
52 designee utilization review company that a request for a benefit under  
53 the health carrier's health benefit plan has been reviewed and, based on  
54 the information provided, satisfies the health carrier's requirements for  
55 medical necessity, appropriateness, health care setting, level of care and  
56 effectiveness.

57 (7) "Clinical peer" means a physician or other health care professional  
58 who (A) holds a nonrestricted license in a state of the United States and  
59 in the same or similar specialty as typically manages the medical  
60 condition, procedure or treatment under review, and (B) for a review  
61 specified under subparagraph (B) or (C) of subdivision (38) of this  
62 section concerning (i) a child or adolescent substance use disorder or a  
63 child or adolescent mental disorder, holds (I) a national board  
64 certification in child and adolescent psychiatry, or (II) a doctoral level  
65 psychology degree with training and clinical experience in the treatment  
66 of child and adolescent substance use disorder or child and adolescent  
67 mental disorder, as applicable, or (ii) an adult substance use disorder or  
68 an adult mental disorder, holds (I) a national board certification in  
69 psychiatry, or (II) a doctoral level psychology degree with training and  
70 clinical experience in the treatment of adult substance use disorders or  
71 adult mental disorders, as applicable.

72 (8) "Clinical review criteria" means the written screening procedures,

73 decision abstracts, clinical protocols and practice guidelines used by the  
74 health carrier to determine the medical necessity and appropriateness  
75 of health care services.

76 (9) "Cohort study" means a prospective evaluation of two groups of  
77 patients with only one group of patients receiving a specific intervention  
78 or specific interventions.

79 (10) "Commissioner" means the Insurance Commissioner.

80 (11) "Concurrent review" means utilization review conducted during  
81 a patient's stay or course of treatment in a facility, the office of a health  
82 care professional or other inpatient or outpatient health care setting,  
83 including home care.

84 (12) "Covered benefits" or "benefits" means health care services to  
85 which a covered person is entitled under the terms of a health benefit  
86 plan.

87 (13) "Covered person" means a policyholder, subscriber, enrollee or  
88 other individual participating in a health benefit plan.

89 (14) "Emergency medical condition" means a medical condition  
90 manifesting itself by acute symptoms of sufficient severity, including  
91 severe pain, such that a prudent layperson with an average knowledge  
92 of health and medicine, acting reasonably, would have believed that the  
93 absence of immediate medical attention would result in serious  
94 impairment to bodily functions or serious dysfunction of a bodily organ  
95 or part, or would place the person's health or, with respect to a pregnant  
96 woman, the health of the woman or her unborn child, in serious  
97 jeopardy.

98 (15) "Emergency services" means, with respect to an emergency  
99 medical condition:

100 (A) A medical screening examination that is within the capability of  
101 the emergency department of a hospital, including ancillary services  
102 routinely available to the emergency department to evaluate such

103 emergency medical condition; and

104 (B) Such further medical examination and treatment, to the extent  
105 they are within the capability of the staff and facilities available at a  
106 hospital, to stabilize a patient.

107 (16) "Evidence-based standard" means the conscientious, explicit and  
108 judicious use of the current best evidence based on an overall systematic  
109 review of medical research when making determinations about the care  
110 of individual patients.

111 (17) "Expert opinion" means a belief or an interpretation by specialists  
112 with experience in a specific area about the scientific evidence  
113 pertaining to a particular service, intervention or therapy.

114 (18) "Facility" means an institution providing health care services or  
115 a health care setting. "Facility" includes a hospital and other licensed  
116 inpatient center, ambulatory surgical or treatment center, skilled  
117 nursing center, residential treatment center, diagnostic, laboratory and  
118 imaging center, and rehabilitation and other therapeutic health care  
119 setting.

120 (19) "Final adverse determination" means an adverse determination  
121 (A) that has been upheld by the health carrier at the completion of its  
122 internal grievance process, or (B) for which the internal grievance  
123 process has been deemed exhausted.

124 (20) "Grievance" means a written complaint or, if the complaint  
125 involves an urgent care request, an oral complaint, submitted by or on  
126 behalf of a covered person regarding:

127 (A) The availability, delivery or quality of health care services,  
128 including a complaint regarding an adverse determination made  
129 pursuant to utilization review;

130 (B) Claims payment, handling or reimbursement for health care  
131 services; or

132 (C) Any matter pertaining to the contractual relationship between a  
133 covered person and a health carrier.

134 (21) (A) "Health benefit plan" means an insurance policy or contract,  
135 certificate or agreement offered, delivered, issued for delivery, renewed,  
136 amended or continued in this state to provide, deliver, arrange for, pay  
137 for or reimburse any of the costs of health care services;

138 (B) "Health benefit plan" does not include:

139 (i) Coverage of the type specified in subdivisions (5) to (9), inclusive,  
140 (14) and (15) of section 38a-469 or any combination thereof;

141 (ii) Coverage issued as a supplement to liability insurance;

142 (iii) Liability insurance, including general liability insurance and  
143 automobile liability insurance;

144 (iv) Workers' compensation insurance;

145 (v) Automobile medical payment insurance;

146 (vi) Credit insurance;

147 (vii) Coverage for on-site medical clinics;

148 (viii) Other insurance coverage similar to the coverages specified in  
149 subparagraphs (B)(ii) to (B)(vii), inclusive, of this subdivision that are  
150 specified in regulations issued pursuant to the Health Insurance  
151 Portability and Accountability Act of 1996, P.L. 104-191, as amended  
152 from time to time, under which benefits for health care services are  
153 secondary or incidental to other insurance benefits;

154 (ix) (I) Limited scope dental or vision benefits, (II) benefits for long-  
155 term care, nursing home care, home health care, community-based care  
156 or any combination thereof, or (III) other similar, limited benefits  
157 specified in regulations issued pursuant to the Health Insurance  
158 Portability and Accountability Act of 1996, P.L. 104-191, as amended  
159 from time to time, provided any benefits specified in subparagraphs

160 (B)(ix)(I) to (B)(ix)(III), inclusive, of this subdivision are provided under  
161 a separate insurance policy, certificate or contract and are not otherwise  
162 an integral part of a health benefit plan; or

163 (x) Coverage of the type specified in subdivisions (3) and (13) of  
164 section 38a-469 or other fixed indemnity insurance if (I) they are  
165 provided under a separate insurance policy, certificate or contract, (II)  
166 there is no coordination between the provision of the benefits and any  
167 exclusion of benefits under any group health plan maintained by the  
168 same plan sponsor, and (III) the benefits are paid with respect to an  
169 event without regard to whether benefits were also provided under any  
170 group health plan maintained by the same plan sponsor.

171 (22) "Health care center" has the same meaning as provided in section  
172 38a-175.

173 (23) "Health care professional" means a physician or other health care  
174 practitioner licensed, accredited or certified to perform specified health  
175 care services consistent with state law.

176 (24) "Health care services" has the same meaning as provided in  
177 section 38a-478.

178 (25) "Health carrier" means an entity subject to the insurance laws and  
179 regulations of this state or subject to the jurisdiction of the  
180 commissioner, that contracts or offers to contract to provide, deliver,  
181 arrange for, pay for or reimburse any of the costs of health care services,  
182 including a sickness and accident insurance company, a health care  
183 center, a managed care organization, a hospital service corporation, a  
184 medical service corporation or any other entity providing a plan of  
185 health insurance, health benefits or health care services.

186 (26) "Health information" means information or data, whether oral or  
187 recorded in any form or medium, and personal facts or information  
188 about events or relationships that relate to (A) the past, present or future  
189 physical, mental, or behavioral health or condition of a covered person  
190 or a member of the covered person's family, (B) the provision of health

191 care services to a covered person, or (C) payment for the provision of  
192 health care services to a covered person.

193 (27) "Independent review organization" means an entity that  
194 conducts independent external reviews of adverse determinations and  
195 final adverse determinations. Such review entities include, but are not  
196 limited to, medical peer review organizations, independent utilization  
197 review companies, provided such organizations or companies are not  
198 related to or associated with any health carrier, and nationally  
199 recognized health experts or institutions approved by the Insurance  
200 Commissioner.

201 (28) "Medical or scientific evidence" means evidence found in the  
202 following sources:

203 (A) Peer-reviewed scientific studies published in or accepted for  
204 publication by medical journals that meet nationally recognized  
205 requirements for scientific manuscripts and that submit most of their  
206 published articles for review by experts who are not part of the editorial  
207 staff;

208 (B) Peer-reviewed medical literature, including literature relating to  
209 therapies reviewed and approved by a qualified institutional review  
210 board, biomedical compendia and other medical literature that meet the  
211 criteria of the National Institutes of Health's Library of Medicine for  
212 indexing in Index Medicus (Medline) or Elsevier Science for indexing in  
213 Excerpta Medicus (EMBASE);

214 (C) Medical journals recognized by the Secretary of the United States  
215 Department of Health and Human Services under Section 1861(t)(2) of  
216 the Social Security Act;

217 (D) The following standard reference compendia: (i) The American  
218 Hospital Formulary Service - Drug Information; (ii) Drug Facts and  
219 Comparisons; (iii) The American Dental Association's Accepted Dental  
220 Therapeutics; and (iv) The United States Pharmacopoeia - Drug  
221 Information;



222 (E) Findings, studies or research conducted by or under the auspices  
223 of federal government agencies and nationally recognized federal  
224 research institutes, including: (i) The Agency for Healthcare Research  
225 and Quality; (ii) the National Institutes of Health; (iii) the National  
226 Cancer Institute; (iv) the National Academy of Sciences; (v) the Centers  
227 for Medicare and Medicaid Services; (vi) the Food and Drug  
228 Administration; and (vii) any national board recognized by the National  
229 Institutes of Health for the purpose of evaluating the medical value of  
230 health care services; or

231 (F) Any other findings, studies or research conducted by or under the  
232 auspices of a source comparable to those listed in subparagraphs (E)(i)  
233 to (E)(v), inclusive, of this subdivision.

234 (29) "Medical necessity" has the same meaning as provided in  
235 sections 38a-482a and 38a-513c.

236 (30) "Participating provider" means a health care professional who,  
237 under a contract with the health carrier, its contractor or subcontractor,  
238 has agreed to provide health care services to covered persons, with an  
239 expectation of receiving payment or reimbursement directly or  
240 indirectly from the health carrier, other than coinsurance, copayments  
241 or deductibles.

242 (31) "Person" has the same meaning as provided in section 38a-1.

243 (32) "Prospective review" means utilization review conducted prior  
244 to an admission or the provision of a health care service or a course of  
245 treatment, in accordance with a health carrier's requirement that such  
246 service or treatment be approved, in whole or in part, prior to such  
247 service's or treatment's provision.

248 (33) "Protected health information" means health information (A) that  
249 identifies an individual who is the subject of the information, or (B) for  
250 which there is a reasonable basis to believe that such information could  
251 be used to identify such individual.

252 (34) "Randomized clinical trial" means a controlled, prospective  
253 study of patients that have been randomized into an experimental  
254 group and a control group at the beginning of the study, with only the  
255 experimental group of patients receiving a specific intervention, and  
256 that includes study of the groups for variables and anticipated outcomes  
257 over time.

258 (35) "Rescission" means a cancellation or discontinuance of coverage  
259 under a health benefit plan that has a retroactive effect. "Rescission"  
260 does not include a cancellation or discontinuance of coverage under a  
261 health benefit plan if (A) such cancellation or discontinuance has a  
262 prospective effect only, or (B) such cancellation or discontinuance is  
263 effective retroactively to the extent it is attributable to the covered  
264 person's failure to timely pay required premiums or contributions  
265 towards the cost of such coverage.

266 (36) "Retrospective review" means any review of a request for a  
267 benefit that is not a prospective review or concurrent review.  
268 "Retrospective review" does not include a review of a request that is  
269 limited to the veracity of documentation or the accuracy of coding.

270 (37) "Stabilize" means, with respect to an emergency medical  
271 condition, that (A) no material deterioration of such condition is likely,  
272 within reasonable medical probability, to result from or occur during  
273 the transfer of the individual from a facility, or (B) with respect to a  
274 pregnant woman, the woman has delivered, including the placenta.

275 (38) "Urgent care request" means a request for a health care service or  
276 course of treatment (A) for which the time period for making a non-  
277 urgent care request determination (i) could seriously jeopardize the life  
278 or health of the covered person or the ability of the covered person to  
279 regain maximum function, or (ii) in the opinion of a health care  
280 professional with knowledge of the covered person's medical condition,  
281 would subject the covered person to severe pain that cannot be  
282 adequately managed without the health care service or treatment being  
283 requested, or (B) for a substance use disorder, as described in section

284 17a-458, or for a co-occurring mental disorder, or (C) for a mental  
285 disorder requiring (i) inpatient services, (ii) partial hospitalization, as  
286 defined in section 38a-496, (iii) residential treatment, or (iv) intensive  
287 outpatient services necessary to keep a covered person from requiring  
288 an inpatient setting.

289 (39) "Utilization review" means the use of a set of formal techniques  
290 designed to monitor the use of, or evaluate the medical necessity,  
291 appropriateness, efficacy or efficiency of, health care services, health  
292 care procedures or health care settings. Such techniques may include the  
293 monitoring of or evaluation of (A) health care services performed or  
294 provided in an outpatient setting, (B) the formal process for  
295 determining, prior to discharge from a facility, the coordination and  
296 management of the care that a patient receives following discharge from  
297 a facility, (C) opportunities or requirements to obtain a clinical  
298 evaluation by a health care professional other than the one originally  
299 making a recommendation for a proposed health care service, (D)  
300 coordinated sets of activities conducted for individual patient  
301 management of serious, complicated, protracted or other health  
302 conditions, or (E) prospective review, concurrent review, retrospective  
303 review or certification.

304 (40) "Utilization review company" means an entity that conducts  
305 utilization review.

306 Sec. 2. (NEW) (*Effective October 1, 2023*) (a) As used in this section:

307 (1) "Evaluation" means:

308 (A) With respect to a health care service or course of treatment for  
309 which a participating provider does not have a prospective or  
310 concurrent review exemption, a review by a health carrier of  
311 prospective or concurrent review requests submitted by such  
312 participating provider during the most recent evaluation period to  
313 determine the percentage of such requests that were approved, for a  
314 health carrier to evaluate whether to grant or deny a prospective or  
315 concurrent review exemption; or

316 (B) With respect to a health care service or course of treatment for  
317 which a participating provider has a prospective or concurrent review  
318 exemption, a retrospective review by a health carrier of a random  
319 sample of payable claims submitted by such participating provider  
320 during the most recent evaluation period to determine the percentage  
321 of claims that would have been approved, based on meeting such health  
322 carrier's applicable medical necessity criteria at the time the service was  
323 provided, for such health carrier to evaluate whether to continue or  
324 rescind a prospective or concurrent review exemption;

325 (2) "Evaluation period" means the six-month period preceding an  
326 evaluation. "Evaluation period" includes:

327 (A) For an initial determination of a prospective or concurrent review  
328 exemption grant or denial for any health care service or course of  
329 treatment, any six-month period that begins on January 1, 2025, July 1,  
330 2025, or any subsequent six-month period that begins on any January  
331 first or July first of any subsequent year;

332 (B) After a denial or rescission of a prospective or concurrent review  
333 exemption for any health care service or course of treatment, the six-  
334 month period that commences on the first day following the end of the  
335 evaluation period that formed the basis of such denial or rescission of a  
336 prospective or concurrent review exemption; and

337 (C) For a notification of a prospective or concurrent review  
338 exemption rescission, the six-month period after the health carrier  
339 provided such notice of rescission to the participating provider or the  
340 next six-month period;

341 (3) "Independent appeal organization" means any entity that  
342 conducts independent external reviews of rescissions of prospective or  
343 concurrent review exemptions. Such entities include, but are not limited  
344 to, medical peer review organizations, independent utilization review  
345 companies, provided such organizations or companies are not related  
346 to or associated with any health carrier, and are nationally recognized  
347 health experts or institutions approved by the commissioner; and

348 (4) "National provider identifier" means a standard, unique health  
349 identifier for each participating provider issued by the federal Centers  
350 for Medicare and Medicaid Services' National Plan and Provider  
351 Enumeration System.

352 (b) For any health care contract entered into, renewed or amended on  
353 or after January 1, 2025, or after an evaluation for an evaluation period  
354 following the date when regulations are first adopted pursuant to  
355 subsection (m) of this section, whichever is later, no health carrier that  
356 provides or performs utilization review, including prospective and  
357 concurrent review, for any health care service or course of treatment  
358 shall require that any participating provider obtain prospective or  
359 concurrent review for any health care service or course of treatment if,  
360 in the immediately preceding six-month evaluation period, such health  
361 carrier approved not less than ninety per cent of such prospective or  
362 concurrent review requests submitted by such participating provider  
363 for such health care service or course of treatment.

364 (c) No health carrier that conducts an evaluation of a health care  
365 service or course of treatment for which a participating provider does  
366 not have an exemption pursuant to subsection (b) of this section from  
367 prospective or concurrent review shall include in such evaluation a  
368 prospective or concurrent review request that is open or pending appeal  
369 with an independent appeal organization pursuant to subsection (n) of  
370 this section. Each evaluation by a health carrier shall be based on not  
371 less than five prospective or concurrent review requests.

372 (d) (1) Not later than sixty days from the end of an evaluation period  
373 of a health care service or course of treatment for which a participating  
374 provider does not have an exemption from prospective or concurrent  
375 review, the health carrier that conducts such evaluation shall provide  
376 written notice to such participating provider of the results of such health  
377 carrier's evaluation.

378 (2) For a health care service or course of treatment for which a  
379 participating provider has a prospective or concurrent review

380 exemption, the health carrier that conducts an evaluation shall provide  
381 written notice to such participating provider of the results of such health  
382 carrier's evaluation not later than the end of the immediately following  
383 January or July, whichever is earlier, following such health carrier's  
384 receipt of medical records from such participating provider pursuant to  
385 the provisions set forth in subsection (l) of this section.

386 (3) Each health carrier providing written notice to a participating  
387 provider pursuant to the provisions set forth in subdivisions (1) and (2)  
388 of this subsection shall include in such notice the following information:

389 (A) Identification of such participating provider's national provider  
390 identifier;

391 (B) A statement that such participating provider qualifies for an  
392 exemption from the prospective or concurrent review requirements;

393 (C) A list of such participating provider's health care services or  
394 course of treatments and health benefit plans to which such exemption  
395 applies; and

396 (D) A statement identifying the duration of such exemption.

397 (e) If a participating provider submits a prospective or concurrent  
398 review request to a health carrier for any health care service or course of  
399 treatment for which such participating provider qualifies for an  
400 exemption from the prospective or concurrent review requirements  
401 pursuant to subsection (b) of this section, such health carrier shall  
402 provide written notice not later than twenty-four hours after such health  
403 carrier receives such request to such participating provider that  
404 includes:

405 (1) The information required under subparagraphs (A) to (D),  
406 inclusive, of subsection (d) of this section; and

407 (2) Notification of such health carrier's payment requirements.

408 (f) Except for any exemption from the prospective or concurrent

409 review requirements that shall continue without evaluation pursuant to  
410 subsection (j) of this section, each health carrier shall conduct an  
411 evaluation once every six months to determine whether each  
412 participating provider qualifies for an exemption from the prospective  
413 or concurrent review requirements pursuant to subsection (b) of this  
414 section.

415 (g) No participating provider shall be required to request an  
416 exemption from the prospective or concurrent review requirements in  
417 order to qualify for such exemption under subsection (b) of this section.

418 (h) (1) No treating health care provider may rely on a participating  
419 provider's exemption from the prospective or concurrent review  
420 requirements set forth in subsection (b) of this section to avoid the  
421 utilization review requirements set forth in sections 38a-591a to 38a-  
422 591n, inclusive, of the general statutes, as amended by this act. If such  
423 treating health care provider relies on a participating provider's  
424 exemption from the prospective or concurrent review requirements for  
425 a particular health care service or course of treatment in violation of this  
426 subsection, the health carrier for such participating provider may find  
427 that such participating provider failed to substantially perform such  
428 health care service or course of treatment under subparagraph (B) of  
429 subdivision (1) of subsection (q) of this section, and may reduce or deny  
430 payment to such participating provider.

431 (2) Nothing in subdivision (1) of this subsection shall be construed to  
432 prohibit a treating health care provider from relying on a participating  
433 provider's exemption from the prospective or concurrent review  
434 requirements pursuant to subsection (b) of this section to render health  
435 care treatment or services to a covered person that would otherwise  
436 require utilization review, provided such treatment or service was  
437 ordered by such participating provider.

438 (3) For purposes of this subsection, "treating health care provider"  
439 means any health care provider who does not have an exemption from  
440 the prospective or concurrent review requirements pursuant to

441 subsection (b) of this section.

442 (i) Each participating provider's exemption from the prospective or  
443 concurrent review requirements pursuant to subsection (b) of this  
444 section, shall remain in effect until:

445 (1) The thirtieth day after the date on which the health carrier notifies  
446 such participating provider of such health carrier's determination to  
447 rescind such exemption in accordance with the provisions of subsection  
448 (k) of this section, provided such participating provider does not appeal  
449 such health carrier's determination in accordance with the provisions of  
450 subsection (n) of this section;

451 (2) If such participating provider appeals such health carrier's  
452 determination in accordance with the provisions of subsection (n) of this  
453 section and the independent appeal organization affirms such health  
454 carrier's determination to rescind such exemption, the fifth day after the  
455 date such independent appeal organization affirms such health carrier's  
456 determination to rescind such exemption; or

457 (3) Notwithstanding subdivision (2) of this subsection, if such  
458 participating provider fails to comply with a medical records request  
459 pursuant to the provisions of subsection (l) of this section, the thirtieth  
460 day after the date on which the participating provider receives a medical  
461 record request from the health carrier pursuant to the provisions of  
462 subsection (l) of this section.

463 (j) If a health carrier does not finalize any determination to rescind  
464 such exemption from the prospective or concurrent review  
465 requirements in accordance with the provisions of subsection (i) of this  
466 section, the participating provider shall automatically satisfy the  
467 requirements for an exemption from the prospective or concurrent  
468 review requirements pursuant to subsection (b) of this section.

469 (k) Each health carrier may rescind any participating provider  
470 exemption from the prospective or concurrent review requirements  
471 under subsection (b) of this section only:



472 (1) By delivering notice in accordance with the provisions set forth in  
473 subdivision (4) of this subsection;

474 (2) During January or July of each year;

475 (3) If such health carrier makes a determination on the basis of a  
476 retrospective review of a random sample of not less than five and not  
477 more than twenty claims submitted by such participating provider  
478 during the most recent evaluation period, that less than ninety per cent  
479 of such claims for the health care service or course of treatment met the  
480 medical necessity criteria that would have been used by such health  
481 carrier when conducting prospective or concurrent review for the health  
482 care service or course of treatment during the relevant evaluation  
483 period; and

484 (4) If such health carrier:

485 (A) Notifies such participating provider, in writing, not less than  
486 thirty days before such rescission is to take effect; and

487 (B) Provides with such notice pursuant to subparagraph (A) of this  
488 subdivision:

489 (i) Identification of each claim included in the review of a random  
490 sample pursuant to subdivision (3) of this subsection;

491 (ii) Such health carrier's determination of whether each claim  
492 satisfied such health carrier's screening criteria;

493 (iii) For any claim found to not satisfy such health carrier's screening  
494 criteria:

495 (I) An explanation of the rationale for finding that such claim failed  
496 to satisfy such health carrier's screening criteria, including, if applicable,  
497 a statement that such finding was based on a failure to submit specified  
498 medical records provided in accordance with subdivision (2) of  
499 subsection (I) of this section;

500 (II) The clinical basis for finding that such claim failed to satisfy such  
501 health carrier's screening criteria;

502 (III) A description of the sources of such screening criteria that such  
503 health carrier used as a guideline in reaching such finding; and

504 (IV) The professional specialty of the clinical peer who made the  
505 determination; and

506 (iv) A plain language description identifying the process for such  
507 participating provider to:

508 (I) Submit an appeal of such rescission; and

509 (II) Seek an independent review of such determination.

510 (l) (1) Each health carrier that conducts a retrospective random  
511 sample review of claims submitted by a participating provider pursuant  
512 to subdivision (3) of subsection (k) of this section may request medical  
513 records or other documents.

514 (2) Each health carrier shall (A) limit such request to not more than  
515 twenty claims for the health care service or course of treatment under  
516 review, and (B) only submit medical record requests to such  
517 participating provider during an evaluation period or not later than  
518 ninety days following the end of an evaluation period.

519 (3) The participating provider shall provide copies of the requested  
520 medical records to the health carrier not later than thirty days following  
521 such participating provider's receipt of such request pursuant to  
522 subdivision (1) of this subsection.

523 (m) No health carrier may deny an exemption from the prospective  
524 or concurrent review requirements set forth in subsection (b) of this  
525 section, unless such health carrier provides the participating provider  
526 with statistics and data for the relevant prospective or concurrent  
527 review evaluation period and information sufficient to demonstrate that  
528 such participating provider failed to meet the criteria for an exemption

529 from the prospective or concurrent review requirements set forth in  
530 subsection (b) of this section for each health care service or course of  
531 treatment.

532 (n) (1) If a health carrier rescinds any participating provider's  
533 exemption from the prospective or concurrent review requirements  
534 pursuant to subsection (k) of this section, such participating provider  
535 may file a request with the commissioner for an independent review of  
536 the rescission of such participating provider's exemption from the  
537 prospective or concurrent review requirements not later than twenty  
538 calendar days after the participating provider receives notice of such  
539 rescission from the health carrier. All requests for independent review  
540 shall be made in writing to the commissioner. The commissioner may  
541 prescribe the form and content of such requests.

542 (2) Not later than one business day after the commissioner receives a  
543 request for independent review, the commissioner shall:

544 (A) Send a copy of such request to the health carrier that issued the  
545 exemption rescission that is the subject of the request; and

546 (B) Assign an independent appeal organization from the list of  
547 approved independent appeal organizations compiled and maintained  
548 by the commissioner to conduct the review and notify the health carrier  
549 of the name of the assigned independent appeal organization. Such  
550 assignment shall be done on a random basis among approved  
551 independent appeal organizations qualified to conduct the particular  
552 review based on the nature of the health care service or treatment that  
553 is the subject of the exemption rescission and other circumstances,  
554 including conflict of interest concerns as determined by the  
555 commissioner pursuant to subdivision (3) of subsection (r) of this  
556 section.

557 (3) Each health carrier that issues any adverse determination of a  
558 participating provider's exemption shall pay the independent appeal  
559 organization for the cost of conducting such independent review.

560 (4) The commissioner may adopt regulations, in accordance with the  
561 provisions of chapter 54 of the general statutes, to implement a  
562 reasonable fee to be paid by any health carrier that requests copies of  
563 documents, communications, information and evidence relating to the  
564 adverse determination of a participating provider's exemption  
565 requested from such participating provider for purposes of such  
566 independent review conducted pursuant to this subsection.

567 (5) The participating provider may request that the independent  
568 appeal organization consider a random sample of not less than five and  
569 not more than twenty claims submitted to the health carrier by such  
570 participating provider during the relevant evaluation period for the  
571 health care service or course of treatment that is subject to such  
572 independent review. If such participating provider requests a review of  
573 such random sample, such independent appeal organization shall base  
574 its determination on the medical necessity of claims reviewed by such  
575 health carrier under subdivision (3) of subsection (k) of this section and  
576 by such independent appeal organization pursuant to this subdivision.

577 (6) Each independent appeal organization shall complete the review  
578 of any adverse determination of the participating provider's exemption  
579 from the prospective and concurrent review requirements not later than  
580 the thirtieth calendar day after the date that such participating provider  
581 files such request with the commissioner for such independent review  
582 under subdivision (1) of this subsection.

583 (o) (1) Each independent review determination shall be binding on  
584 the health carrier and the participating provider, except to the extent  
585 such health carrier or participating provider has other remedies  
586 available under federal or state law.

587 (2) No health carrier shall retroactively deny any health care service  
588 or course of treatment on the basis of a rescission of an exemption, even  
589 if such health carrier's determination to rescind such prospective or  
590 concurrent review exemption is affirmed by an independent appeal  
591 organization.

592 (3) If any independent appeal organization overturns any health  
593 carrier's determination of a prospective or concurrent review  
594 exemption, such health carrier:

595 (A) Shall not attempt to rescind such exemption before the end of the  
596 next evaluation period; and

597 (B) May only rescind such exemption after the end of the next  
598 evaluation period, provided such health carrier complies with the  
599 provisions of subsections (k) to (n), inclusive, of this section.

600 (p) After a determination or review affirming a rescission or denial of  
601 an exemption from the prospective or concurrent review requirements  
602 for a health care service or course of treatment, any participating  
603 provider shall be eligible for reconsideration of such exemption for the  
604 same health care service or course of treatment beginning with the  
605 evaluation period that was in effect on the date that such participating  
606 provider received the health carrier's notice of determination to rescind  
607 or deny such exemption in accordance with the provisions of subsection  
608 (k) of this section.

609 (q) (1) No health carrier shall deny or reduce payment to a  
610 participating provider for any health care service or course of treatment  
611 for which such participating provider has qualified for an exemption  
612 from the prospective or concurrent review requirements pursuant to  
613 subsection (b) of this section based on medical necessity or  
614 appropriateness of care, unless such participating provider:

615 (A) Knowingly and materially misrepresented such health care  
616 service or course of treatment in a request for payment submitted to  
617 such health carrier; or

618 (B) Failed to substantially perform such health care service or course  
619 of treatment.

620 (2) No health carrier shall conduct a retrospective review of any  
621 health care service or course of treatment subject to an exemption

622 pursuant to subsection (b) of this section, except:

623 (A) To determine if a participating provider qualifies for such  
624 exemption; or

625 (B) If such health carrier has reasonable cause to believe that a basis  
626 for denial exists under subdivision (1) of this subsection.

627 (r) The commissioner shall adopt regulations, in accordance with the  
628 provisions of chapter 54 of the general statutes, to implement the  
629 provisions of this section. Not later than March 1, 2024, the  
630 commissioner shall submit proposed regulations for public comment  
631 pursuant to section 4-168 of the general statutes. Such regulations shall  
632 include, but need not be limited to:

633 (1) The establishment of uniform disclosure requirements for health  
634 carriers when a participating provider appeals an exemption from the  
635 prospective or concurrent review requirements;

636 (2) The establishment of a procedure for the assignment of appeals to  
637 independent appeal organizations;

638 (3) A determination of circumstances that constitute conflicts of  
639 interest between independent appeal organizations assigned to conduct  
640 independent reviews of exemption rescissions and health carriers and  
641 participating providers; and

642 (4) The establishment of uniform filing instructions for a participating  
643 provider to file an appeal of a rescission of such participating provider's  
644 exemption from the prospective or concurrent review requirements.

645 Sec. 3. (NEW) (*Effective January 1, 2024*) No health carrier shall require  
646 a prospective or concurrent review of a recurring prescription drug after  
647 such health carrier has certified such prescription drug through  
648 utilization review. Nothing in this section shall require a health carrier  
649 to cover any prescription drug for a health condition if the terms of  
650 coverage completely exclude such prescription drug from the policy's  
651 covered benefits, or cover a brand name drug when an equivalent

652 generic drug is available.

653 Sec. 4. Section 38a-591d of the general statutes is repealed and the  
654 following is substituted in lieu thereof (*Effective January 1, 2024*):

655 (a) (1) Each health carrier shall maintain written procedures for (A)  
656 utilization review and benefit determinations, (B) expedited utilization  
657 review and benefit determinations with respect to prospective urgent  
658 care requests and concurrent review urgent care requests, and (C)  
659 notifying covered persons or covered persons' authorized  
660 representatives of such review and benefit determinations. Each health  
661 carrier shall make such review and benefit determinations within the  
662 specified time periods under this section.

663 (2) In determining whether a benefit request shall be considered an  
664 urgent care request, an individual acting on behalf of a health carrier  
665 shall apply the judgment of a prudent layperson who possesses an  
666 average knowledge of health and medicine, except that any benefit  
667 request (A) determined to be an urgent care request by a health care  
668 professional with knowledge of the covered person's medical condition,  
669 or (B) specified under subparagraph (B) or (C) of subdivision (38) of  
670 section 38a-591a, as amended by this act, shall be deemed an urgent care  
671 request.

672 (3) (A) At the time a health carrier notifies a covered person, a covered  
673 person's authorized representative or a covered person's health care  
674 professional of an initial adverse determination that was based, in whole  
675 or in part, on medical necessity, of a concurrent or prospective  
676 utilization review or of a benefit request, the health carrier shall notify  
677 the covered person's health care professional (i) of the opportunity for a  
678 conference as provided in subparagraph (B) of this subdivision, and (ii)  
679 that such conference shall not be considered a grievance of such initial  
680 adverse determination as long as a grievance has not been filed as set  
681 forth in subparagraph (B) of this subdivision.

682 (B) After a health carrier notifies a covered person, a covered person's  
683 authorized representative or a covered person's health care professional

684 of an initial adverse determination that was based, in whole or in part,  
685 on medical necessity, of a concurrent or prospective utilization review  
686 or of a benefit request, the health carrier shall offer a covered person's  
687 health care professional the opportunity to confer, at the request of the  
688 covered person's health care professional, with a clinical peer of such  
689 health carrier, provided such covered person, covered person's  
690 authorized representative or covered person's health care professional  
691 has not filed a grievance of such initial adverse determination prior to  
692 such conference. Such conference shall not be considered a grievance of  
693 such initial adverse determination.

694 (b) With respect to a nonurgent care request:

695 (1) (A) For a prospective or concurrent review request, a health carrier  
696 shall make a determination within a reasonable period of time  
697 appropriate to the covered person's medical condition, but not later than  
698 [fifteen] five calendar days after the date the health carrier receives such  
699 request, and shall notify the covered person and, if applicable, the  
700 covered person's authorized representative of such determination,  
701 whether or not the carrier certifies the provision of the benefit.

702 (B) If the review under subparagraph (A) of this subdivision is a  
703 review of a grievance involving a concurrent review request, pursuant  
704 to 45 CFR 147.136, as amended from time to time, the treatment shall be  
705 continued without liability to the covered person until the covered  
706 person has been notified of the review decision.

707 (2) For a retrospective review request, a health carrier shall make a  
708 determination within a reasonable period of time, but not later than  
709 thirty calendar days after the date the health carrier receives such  
710 request.

711 (3) (A) The time [periods] period specified in [subdivisions (1) and  
712 (2)] subdivision (1) of this subsection may be extended once by the  
713 health carrier for up to [fifteen] five calendar days, and the time period  
714 specified in subdivision (2) of this subsection may be extended once by  
715 the health carrier for up to fifteen calendar days, provided the health



716 carrier:

717 [(A)] (i) Determines that an extension is necessary due to  
718 circumstances beyond the health carrier's control; and

719 [(B)] (ii) Notifies the covered person and, if applicable, the covered  
720 person's authorized representative prior to the expiration of the initial  
721 time period, of the circumstances requiring the extension of time and  
722 the date by which the health carrier expects to make a determination.

723 (B) Notwithstanding the provisions of subparagraph (A) of  
724 subdivision (3) of this subsection, the time period specified in  
725 subdivision (1) of this subsection may be extended once by the health  
726 carrier for up to fifteen calendar days, provided the covered person's  
727 health care professional notifies the health carrier that the service will  
728 not be performed for at least three months from the date such health  
729 carrier received the request.

730 (4) (A) If the extension pursuant to subdivision (3) of this subsection  
731 is necessary due to the failure of the covered person or the covered  
732 person's authorized representative to provide information necessary to  
733 make a determination on the request, the health carrier shall:

734 (i) Specifically describe in the notice of extension the required  
735 information necessary to complete the request; and

736 (ii) Provide the covered person and, if applicable, the covered  
737 person's authorized representative with not less than forty-five calendar  
738 days after the date of receipt of the notice to provide the specified  
739 information.

740 (B) If the covered person or the covered person's authorized  
741 representative fails to submit the specified information before the end  
742 of the period of the extension, the health carrier may deny certification  
743 of the benefit requested.

744 (c) With respect to an urgent care request:

745 (1) (A) Unless the covered person or the covered person's authorized  
746 representative has failed to provide information necessary for the health  
747 carrier to make a determination and except as specified under  
748 subparagraph (B) of this subdivision, the health carrier shall make a  
749 determination as soon as possible, taking into account the covered  
750 person's medical condition, but not later than [forty-eight] twenty-four  
751 hours after the health carrier receives such request, [or seventy-two  
752 hours after such health carrier receives such request if any portion of  
753 such forty-eight-hour period falls on a weekend,] provided, if the urgent  
754 care request is a concurrent review request to extend a course of  
755 treatment beyond the initial period of time or the number of treatments,  
756 such request is made [at least] not less than twenty-four hours prior to  
757 the expiration of the prescribed period of time or number of treatments.

758 (B) Unless the covered person or the covered person's authorized  
759 representative has failed to provide information necessary for the health  
760 carrier to make a determination, for an urgent care request specified  
761 under subparagraph (B) or (C) of subdivision (38) of section 38a-591a,  
762 as amended by this act, the health carrier shall make a determination as  
763 soon as possible, taking into account the covered person's medical  
764 condition, but not later than twenty-four hours after the health carrier  
765 receives such request, provided, if the urgent care request is a  
766 concurrent review request to extend a course of treatment beyond the  
767 initial period of time or the number of treatments, such request is made  
768 [at least] not less than twenty-four hours prior to the expiration of the  
769 prescribed period of time or number of treatments.

770 (2) (A) If the covered person or the covered person's authorized  
771 representative has failed to provide information necessary for the health  
772 carrier to make a determination, the health carrier shall notify the  
773 covered person or the covered person's representative, as applicable, as  
774 soon as possible, but not later than twenty-four hours after the health  
775 carrier receives such request.

776 (B) The health carrier shall provide the covered person or the covered  
777 person's authorized representative, as applicable, a reasonable period of

778 time to submit the specified information, taking into account the  
779 covered person's medical condition, but not less than forty-eight hours  
780 after notifying the covered person or the covered person's authorized  
781 representative, as applicable.

782 (3) The health carrier shall notify the covered person and, if  
783 applicable, the covered person's authorized representative of its  
784 determination as soon as possible, but not later than forty-eight hours  
785 after the earlier of (A) the date on which the covered person and the  
786 covered person's authorized representative, as applicable, provides the  
787 specified information to the health carrier, or (B) the date on which the  
788 specified information was to have been submitted.

789 (d) (1) Whenever a health carrier receives a review request from a  
790 covered person or a covered person's authorized representative that  
791 fails to meet the health carrier's filing procedures, the health carrier shall  
792 notify the covered person and, if applicable, the covered person's  
793 authorized representative of such failure not later than five calendar  
794 days after the health carrier receives such request, except that for an  
795 urgent care request, the health carrier shall notify the covered person  
796 and, if applicable, the covered person's authorized representative of  
797 such failure not later than twenty-four hours after the health carrier  
798 receives such request. For a nonurgent prospective or concurrent review  
799 request, each health carrier shall acknowledge receipt of each such  
800 request as soon as practicable, but not later than twenty-four hours after  
801 the health carrier receives such request, except that such health carrier  
802 shall respond in less time if such a response is required by applicable  
803 federal law.

804 (2) If the health carrier provides such notice orally, the health carrier  
805 shall provide confirmation in writing to the covered person and the  
806 covered person's health care professional of record not later than [five]  
807 three calendar days after providing the oral notice. No health carrier  
808 shall require a health care professional or hospital to submit additional  
809 information that was not reasonably available to such health care  
810 professional or hospital at the time that such health care professional or

811 hospital filed the prospective or concurrent review request with such  
812 health carrier.

813 (e) Each health carrier shall provide promptly to a covered person  
814 and, if applicable, the covered person's authorized representative a  
815 notice of an adverse determination.

816 (1) Such notice may be provided in writing or by electronic means  
817 and shall set forth, in a manner calculated to be understood by the  
818 covered person or the covered person's authorized representative:

819 (A) Information sufficient to identify the benefit request or claim  
820 involved, including the date of service, if applicable, the health care  
821 professional and the claim amount;

822 (B) The specific reason or reasons for the adverse determination,  
823 including, upon request, a listing of the relevant clinical review criteria,  
824 including professional criteria and medical or scientific evidence and a  
825 description of the health carrier's standard, if any, that were used in  
826 reaching the denial;

827 (C) Reference to the specific health benefit plan provisions on which  
828 the determination is based;

829 (D) A description of any additional material or information necessary  
830 for the covered person to perfect the benefit request or claim, including  
831 an explanation of why the material or information is necessary to perfect  
832 the request or claim;

833 (E) A description of the health carrier's internal grievance process that  
834 includes (i) the health carrier's expedited review procedures, (ii) any  
835 time limits applicable to such process or procedures, (iii) the contact  
836 information for the organizational unit designated to coordinate the  
837 review on behalf of the health carrier, and (iv) a statement that the  
838 covered person or, if applicable, the covered person's authorized  
839 representative is entitled, pursuant to the requirements of the health  
840 carrier's internal grievance process, to receive from the health carrier,

841 free of charge upon request, reasonable access to and copies of all  
842 documents, records, communications and other information and  
843 evidence regarding the covered person's benefit request;

844 (F) (i) (I) A copy of the specific rule, guideline, protocol or other  
845 similar criterion the health carrier relied upon to make the adverse  
846 determination, or (II) a statement that a specific rule, guideline, protocol  
847 or other similar criterion of the health carrier was relied upon to make  
848 the adverse determination and that a copy of such rule, guideline,  
849 protocol or other similar criterion will be provided to the covered person  
850 free of charge upon request, with instructions for requesting such copy,  
851 and (ii) the links to such rule, guideline, protocol or other similar  
852 criterion on such health carrier's Internet web site;

853 (G) If the adverse determination is based on medical necessity or an  
854 experimental or investigational treatment or similar exclusion or limit,  
855 the written statement of the scientific or clinical rationale for the adverse  
856 determination and (i) an explanation of the scientific or clinical rationale  
857 used to make the determination that applies the terms of the health  
858 benefit plan to the covered person's medical circumstances, or (ii) a  
859 statement that an explanation will be provided to the covered person  
860 free of charge upon request, and instructions for requesting a copy of  
861 such explanation;

862 (H) A statement explaining the right of the covered person to contact  
863 the commissioner's office or the Office of the Healthcare Advocate at  
864 any time for assistance or, upon completion of the health carrier's  
865 internal grievance process, to file a civil action in a court of competent  
866 jurisdiction. Such statement shall include the contact information for  
867 said offices; and

868 (I) A statement, expressed in language approved by the Healthcare  
869 Advocate and prominently displayed on the first page or cover sheet of  
870 the notice using a call-out box and large or bold text, that if the covered  
871 person or the covered person's authorized representative chooses to file  
872 a grievance of an adverse determination, (i) such appeals are sometimes

873 successful, (ii) such covered person or covered person's authorized  
874 representative may benefit from free assistance from the Office of the  
875 Healthcare Advocate, which can assist such covered person or covered  
876 person's authorized representative with the filing of a grievance  
877 pursuant to 42 USC 300gg-93, as amended from time to time, (iii) such  
878 covered person or covered person's authorized representative is entitled  
879 and encouraged to submit supporting documentation for the health  
880 carrier's consideration during the review of an adverse determination,  
881 including narratives from such covered person or covered person's  
882 authorized representative and letters and treatment notes from such  
883 covered person's health care professional, and (iv) such covered person  
884 or covered person's authorized representative has the right to ask such  
885 covered person's health care professional for such letters or treatment  
886 notes.

887 (2) Upon request pursuant to subparagraph (E) of subdivision (1) of  
888 this subsection, the health carrier shall provide such copies in  
889 accordance with subsection (a) of section 38a-591n.

890 (f) If the adverse determination is a rescission, the health carrier shall  
891 include with the advance notice of the application for rescission  
892 required to be sent to the covered person, a written statement that  
893 includes:

894 (1) Clear identification of the alleged fraudulent act, practice or  
895 omission or the intentional misrepresentation of material fact;

896 (2) An explanation as to why the act, practice or omission was  
897 fraudulent or was an intentional misrepresentation of a material fact;

898 (3) A disclosure that the covered person or the covered person's  
899 authorized representative may file immediately, without waiting for the  
900 date such advance notice of the proposed rescission ends, a grievance  
901 with the health carrier to request a review of the adverse determination  
902 to rescind coverage, pursuant to sections 38a-591e and 38a-591f;

903 (4) A description of the health carrier's grievance procedures

904 established under sections 38a-591e and 38a-591f, including any time  
905 limits applicable to those procedures; and

906 (5) The date such advance notice of the proposed rescission ends and  
907 the date back to which the coverage will be retroactively rescinded.

908 (g) (1) Whenever a health carrier fails to strictly adhere to the  
909 requirements of this section with respect to making utilization review  
910 and benefit determinations of a benefit request or claim, the covered  
911 person shall be deemed to have exhausted the internal grievance  
912 process of such health carrier and may file a request for an external  
913 review in accordance with the provisions of section 38a-591g, regardless  
914 of whether the health carrier asserts it substantially complied with the  
915 requirements of this section or that any error it committed was de  
916 minimis.

917 (2) A covered person who has exhausted the internal grievance  
918 process of a health carrier may, in addition to filing a request for an  
919 external review, pursue any available remedies under state or federal  
920 law on the basis that the health carrier failed to provide a reasonable  
921 internal grievance process that would yield a decision on the merits of  
922 the claim.

923 Sec. 5. Section 38a-490 of the general statutes is repealed and the  
924 following is substituted in lieu thereof (*Effective January 1, 2024*):

925 (a) Each individual health insurance policy delivered, issued for  
926 delivery, renewed, amended or continued in this state providing  
927 coverage of the type specified in subdivisions (1), (2), (4), [(6),] (10), (11)  
928 and (12) of section 38a-469 for a family member of the insured or  
929 subscriber shall, as to such family member's coverage, also provide that  
930 the health insurance benefits applicable for children shall be payable  
931 with respect to a newly born child of the insured or subscriber from the  
932 moment of birth.

933 (b) Coverage for such newly born child shall consist of coverage for  
934 injury and sickness including necessary care and treatment of medically

935 diagnosed congenital defects and birth abnormalities within the limits  
936 of the policy.

937 (c) If payment of a specific premium or subscription fee is required to  
938 provide coverage for a child, the policy or contract may require that  
939 notification of birth of such newly born child and payment of the  
940 required premium or fees shall be furnished to the insurer, hospital  
941 service corporation, medical service corporation or health care center  
942 not later than [sixty-one] ninety-one days after the date of birth in order  
943 to continue coverage beyond such [sixty-one-day] period, provided  
944 failure to furnish such notice or pay such premium or fees shall not  
945 prejudice any claim originating within such [sixty-one-day] period.

946 Sec. 6. Section 38a-516 of the general statutes is repealed and the  
947 following is substituted in lieu thereof (*Effective January 1, 2024*):

948 (a) Each group health insurance policy delivered, issued for delivery,  
949 renewed, amended or continued in this state providing coverage of the  
950 type specified in subdivisions (1), (2), (4), [(6),] (11) and (12) of section  
951 38a-469 for a family member of the insured or subscriber shall, as to such  
952 family member's coverage, also provide that the health insurance  
953 benefits applicable for children shall be payable with respect to a newly  
954 born child of the insured or subscriber from the moment of birth.

955 (b) Coverage for such newly born child shall consist of coverage for  
956 injury and sickness including necessary care and treatment of medically  
957 diagnosed congenital defects and birth abnormalities within the limits  
958 of the policy.

959 (c) If payment of a specific premium fee is required to provide  
960 coverage for a child, the policy may require that notification of birth of  
961 such newly born child and payment of the required premium or fees  
962 shall be furnished to the insurer, hospital service corporation, medical  
963 service corporation or health care center not later than [sixty-one]  
964 ninety-one days after the date of birth in order to continue coverage  
965 beyond such [sixty-one-day] period, provided failure to furnish such  
966 notice or pay such premium shall not prejudice any claim originating



967 within such [sixty-one-day] period.

968 Sec. 7. Subsection (a) of section 38a-510 of the general statutes is  
969 repealed and the following is substituted in lieu thereof (*Effective January*  
970 *1, 2024*):

971 (a) No insurance company, hospital service corporation, medical  
972 service corporation, health care center or other entity delivering, issuing  
973 for delivery, renewing, amending or continuing an individual health  
974 insurance policy or contract that provides coverage for prescription  
975 drugs may:

976 (1) Require any person covered under such policy or contract to  
977 obtain prescription drugs from a mail order pharmacy as a condition of  
978 obtaining benefits for such drugs; or

979 (2) Require, if such insurance company, hospital service corporation,  
980 medical service corporation, health care center or other entity uses step  
981 therapy for such drugs, the use of step therapy for (A) any prescribed  
982 drug for longer than [sixty] thirty days, or (B) a prescribed drug for  
983 cancer treatment for an insured who has been diagnosed with stage IV  
984 metastatic cancer provided such prescribed drug is in compliance with  
985 approved federal Food and Drug Administration indications.

986 (3) At the expiration of the time period specified in subparagraph (A)  
987 of subdivision (2) of this subsection or for a prescribed drug described  
988 in subparagraph (B) of subdivision (2) of this subsection, an insured's  
989 treating health care provider may deem such step therapy drug regimen  
990 clinically ineffective for the insured, at which time the insurance  
991 company, hospital service corporation, medical service corporation,  
992 health care center or other entity shall authorize dispensation of and  
993 coverage for the drug prescribed by the insured's treating health care  
994 provider, provided such drug is a covered drug under such policy or  
995 contract. If such provider does not deem such step therapy drug  
996 regimen clinically ineffective or has not requested an override pursuant  
997 to subdivision (1) of subsection (b) of this section, such drug regimen  
998 may be continued. For purposes of this section, "step therapy" means a

999 protocol or program that establishes the specific sequence in which  
1000 prescription drugs for a specified medical condition are to be prescribed.

1001 Sec. 8. Subsection (a) of section 38a-544 of the general statutes is  
1002 repealed and the following is substituted in lieu thereof (*Effective January*  
1003 *1, 2024*):

1004 (a) No insurance company, hospital service corporation, medical  
1005 service corporation, health care center or other entity delivering, issuing  
1006 for delivery, renewing, amending or continuing a group health  
1007 insurance policy or contract that provides coverage for prescription  
1008 drugs may:

1009 (1) Require any person covered under such policy or contract to  
1010 obtain prescription drugs from a mail order pharmacy as a condition of  
1011 obtaining benefits for such drugs; or

1012 (2) Require, if such insurance company, hospital service corporation,  
1013 medical service corporation, health care center or other entity uses step  
1014 therapy for such drugs, the use of step therapy for (A) any prescribed  
1015 drug for longer than [sixty] thirty days, or (B) a prescribed drug for  
1016 cancer treatment for an insured who has been diagnosed with stage IV  
1017 metastatic cancer provided such prescribed drug is in compliance with  
1018 approved federal Food and Drug Administration indications.

1019 (3) At the expiration of the time period specified in subparagraph (A)  
1020 of subdivision (2) of this subsection or for a prescribed drug described  
1021 in subparagraph (B) of subdivision (2) of this subsection, an insured's  
1022 treating health care provider may deem such step therapy drug regimen  
1023 clinically ineffective for the insured, at which time the insurance  
1024 company, hospital service corporation, medical service corporation,  
1025 health care center or other entity shall authorize dispensation of and  
1026 coverage for the drug prescribed by the insured's treating health care  
1027 provider, provided such drug is a covered drug under such policy or  
1028 contract. If such provider does not deem such step therapy drug  
1029 regimen clinically ineffective or has not requested an override pursuant  
1030 to subdivision (1) of subsection (b) of this section, such drug regimen

1031 may be continued. For purposes of this section, "step therapy" means a  
 1032 protocol or program that establishes the specific sequence in which  
 1033 prescription drugs for a specified medical condition are to be  
 1034 prescribed."

This act shall take effect as follows and shall amend the following sections:

Section 1	<i>October 1, 2023</i>	38a-591a
Sec. 2	<i>October 1, 2023</i>	New section
Sec. 3	<i>January 1, 2024</i>	New section
Sec. 4	<i>January 1, 2024</i>	38a-591d
Sec. 5	<i>January 1, 2024</i>	38a-490
Sec. 6	<i>January 1, 2024</i>	38a-516
Sec. 7	<i>January 1, 2024</i>	38a-510(a)
Sec. 8	<i>January 1, 2024</i>	38a-544(a)